Proximagen Neuroscience is a research-based pharmaceutical company focusing on the development of drugs for treating neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease. Proximagen’s areas of expertise include predictive models of drug action in neurodegenerative disease, biochemical, histological, immunocytochemical and in situ hybridization assessments of treatment-based concepts, development of symptom-based treatments for neurodegenerative treatments and for the utilization of model systems for the study of cell death mechanisms for the development of neuroprotective and/or neurorestorative treatment stragies. Proximagen includes preclinical program such as PRX1, for treating Parkinson’s disease, PRX2, for inhibitng L-DOPA-induced dyskinesia in Parkinson’s disease, PRX4, for treating neurodegenerative diseases and PRX5 for treating age-related cognitive disorder.